[Criticism against the atenolol meta-analysis remains].
作者信息
Forsén Kent
出版信息
Lakartidningen. 2005;102(6):412, 414; discussion 414-5.
PMID:15754686
Abstract
摘要
相似文献
1
[Criticism against the atenolol meta-analysis remains].
Lakartidningen. 2005;102(6):412, 414; discussion 414-5.
2
[Noticeable meta-analysis of atenolol does not cover all aspects].
Lakartidningen. 2005;102(1-2):61-3.
3
[Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].
MMW Fortschr Med. 2002 Sep 19;144(38):14.
4
[The double messages about atenolol must be an issue for the SBU board].
Lakartidningen. 2004 Dec 2;101(49):4038, 4041; discussion 4041-2, 4045.
5
[German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
MMW Fortschr Med. 2002 Sep 19;144(38):47.
6
[What are the consequences of the LIFE Study for general practice].
MMW Fortschr Med. 2002 Sep 19;144(38):48.
7
[An article in Lancet set a SBU report rocking. When SBU authors question their own conclusions: Who is to be trusted?].
Lakartidningen. 2005;102(9):617-8.
8
[Beta blockers in hypertension treatment Will stepping back come soon?].
MMW Fortschr Med. 2007 Mar 15;149(11):6.
9
Atenolol and cardiovascular risk: an issue close to the heart.
Lancet. 2006 Feb 25;367(9511):627-9. doi: 10.1016/S0140-6736(06)68238-X.
10
Atenolol versus other beta-adrenergic blockers.
J Am Coll Cardiol. 2009 Jun 2;53(22):2101-2; author reply 2106-7. doi: 10.1016/j.jacc.2008.11.067.
Zotero 插件